TY - JOUR
T1 - Neuroprotective effect of curcumin and curcumin-integrated nanocarriers in stroke
T2 - from mechanisms to therapeutic opportunities
AU - Sharifi-Rad, Javad
AU - Almarhoon, Zainab M.
AU - Adetunji, Charles O.
AU - Samuel Michael, Olugbenga
AU - Chandran, Deepak
AU - Radha, Radha
AU - Sharma, Niharika
AU - Kumar, Manoj
AU - Calina, Daniela
N1 - Publisher Copyright:
© 2022 EDIZIONI MINERVA MEDICA.
PY - 2022/12
Y1 - 2022/12
N2 - Stroke remains one of the world’s leading causes of death and disability. Curcumin, a bioactive component of turmeric derived from Curcuma longa Linn’s rhizomes, has a variety of pharmacological activities. Native curcumin’s therapeutic use against stroke has been limited by its low solubility, poor bioavailability, rapid metabolism, physicochemical instability, and poor pharmacokinetics. By implementing a more effective delivery system, these difficulties can be addressed. Encapsulating or putting curcumin into nanoformulations has been used to increase its pharmacokinetics, systemic bioavailability, and biological activity. A vast number of nanoformulations have been approved for therapeutic use following the conclusion of preclinical and human clinical trials. In light of this, the current updated review discusses the evidence, current status and molecular mechanisms underlying the therapeutic applications of curcumin and nanocurcumin formulations against stroke.
AB - Stroke remains one of the world’s leading causes of death and disability. Curcumin, a bioactive component of turmeric derived from Curcuma longa Linn’s rhizomes, has a variety of pharmacological activities. Native curcumin’s therapeutic use against stroke has been limited by its low solubility, poor bioavailability, rapid metabolism, physicochemical instability, and poor pharmacokinetics. By implementing a more effective delivery system, these difficulties can be addressed. Encapsulating or putting curcumin into nanoformulations has been used to increase its pharmacokinetics, systemic bioavailability, and biological activity. A vast number of nanoformulations have been approved for therapeutic use following the conclusion of preclinical and human clinical trials. In light of this, the current updated review discusses the evidence, current status and molecular mechanisms underlying the therapeutic applications of curcumin and nanocurcumin formulations against stroke.
KW - Blood-Brain Barrier
KW - Curcumin
KW - Nanotechnology
KW - Neuroprotection
KW - Oxidative stress
KW - Stroke
UR - https://www.scopus.com/pages/publications/85143867836
U2 - 10.23736/S2724-542X.22.02946-7
DO - 10.23736/S2724-542X.22.02946-7
M3 - Artículo de revisión
AN - SCOPUS:85143867836
SN - 2724-542X
VL - 34
SP - 153
EP - 169
JO - Minerva Biotechnology and Biomolecular Research
JF - Minerva Biotechnology and Biomolecular Research
IS - 4
ER -